Research Cofactor
$55.00
Research identity: oxidized nicotinamide adenine dinucleotide, a cellular redox cofactor and enzyme substrate—not a peptide.
Catalog scope: 500 mg is the listed material content—not a dose, schedule, route, or use instruction. Purity alone does not establish identity, sterility, endotoxin control, fill accuracy, or stability. For laboratory research only; not for human or veterinary use.
BUILD ONE COMPLETE LIST
Add this item, keep browsing, and add every product or option you need. Your list stays saved in this browser until you send one complete email request or remove it.
RESEARCH HERE · COMPOUND DOSSIER
Plain-language identity, mechanism, evidence maturity, study endpoints, limitations, and direct source records—organized for careful reading, never copied from a dosing site.
CELLULAR REDOX COFACTOR
Oxidized nicotinamide adenine dinucleotide is a ubiquitous cellular cofactor involved in redox chemistry and enzyme systems. Direct exogenous NAD+, its reduced form NADH, and precursors such as NR or NMN are different evidence objects.
01
NAD+ is the oxidized member of the NAD redox pair and participates in cellular electron-transfer chemistry. It also serves as a substrate for enzymes including sirtuins, PARPs, and CD38.
Identity rule: biochemical importance inside cells does not by itself prove a benefit from an exogenous catalog material.
02
03
EVIDENCE SNAPSHOT
The direct human record is small. Regulatory quality reports add an independent warning: material grade, sterility, and endotoxin control are separate from a molecule’s biochemical role.
Eight exposed participants and three controls; focused on metabolome and excretion patterns rather than clinical efficacy.
PMID 31572171 ↗ 2026 · RETROSPECTIVE PILOTShort-term tolerability comparisonSmall observational record reporting gastrointestinal symptoms, heart-rate change, and chest pressure during NAD+ infusions.
PMID 41704678 ↗ FDA · QUALITY ALERTIngredients suitable for sterile compoundingFDA describes adverse-event reports and warns that food-grade NAD+ is unsuitable for sterile drug compounding without appropriate processing.
FDA RECORD ↗DETAILED COMPOUND GUIDE
NAD+ is central to biology, which makes it easy for commercial pages to jump from mechanism to promised outcomes. The direct-material evidence is much narrower.
PubChem identifies NAD+ as oxidized nicotinamide adenine dinucleotide, also called nadide. The NAD+/NADH pair carries electrons in many metabolic reactions, while NAD+-consuming enzymes connect it to signaling and repair pathways.
Those endogenous functions establish biological relevance. They do not establish that an external 500 mg material changes a clinical outcome.
A small 2019 pilot mapped metabolites and excretion during a controlled six-hour exposure. It was designed primarily to study metabolic fate, not to prove anti-aging, energy, cognitive, or weight outcomes.
A 2026 retrospective pilot compared NAD+ with nicotinamide riboside infusion experiences. It reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during NAD+ exposure. Small observational designs cannot establish comprehensive safety or efficacy.
A positive or negative result for a precursor cannot be pasted onto direct NAD+ material. Route, metabolism, formulation, dose, population, and endpoint all matter.
Commercial guides claim energy, DNA repair, cognition, cardiovascular support, weight management, skin effects, immune support, and anti-aging. Direct controlled evidence establishing those clinical outcomes for a 500 mg catalog vial was not found.
There is no FDA-approved wellness label supplying a complete contraindication or interaction list. The limited human record and FDA reports include nausea, vomiting, chills, shaking, abdominal or gastrointestinal symptoms, increased heart rate, and chest pressure in particular exposure or quality contexts.
FDA has warned compounders about using food-grade NAD+ in sterile drug products and has documented endotoxin-related problems. A laboratory purity percentage does not establish sterility, bacterial endotoxin limits, particulate control, fill accuracy, or suitability for any route.
Exact storage, solvent compatibility, concentration, stability, and beyond-use claims require the manufacturer’s batch-specific validated documentation. This dossier provides no preparation or administration method.
ESTABLISHED BIOCHEMISTRYCellular redox-cofactor and enzyme-substrate roles
LIMITED HUMAN RECORDMetabolic-fate and short-term tolerability observations
NOT ESTABLISHED FOR THIS VIALAnti-aging, energy, cognition, weight, cardiovascular, skin, or immune benefits
QUALITY NOT INFERABLESterility, endotoxin control, identity, fill amount, and stability without batch evidence
RESEARCH PROTOCOL MAP
This is a non-prescriptive study-design checklist. It does not supply a human dose, route, schedule, preparation method, or administration instruction.
Specify whether the question concerns NAD+, NADH, NR, NMN, niacinamide, or an endogenous measurement. Do not substitute precursor literature for direct NAD+ evidence.
Document lot-linked identity, assay, degradants, fill amount, and stability. Where the approved laboratory workflow requires it, treat sterility, endotoxin, and particulates as separate tests.
Record the model, comparator, handling controls, measurable primary endpoint, observation window, exclusions, and analysis plan before evaluating results.
Distinguish biochemical role from an external-material effect, and a measured biomarker from a clinical outcome. Log negative, ambiguous, and quality-failed results.
REFERENCE DESK
Commercial NAD+ guide topics are retained as an index, then checked against direct human records, regulatory quality alerts, and the distinction between NAD+ and its precursors.
BENEFITS CLAIM INDEX
BIOCHEMICAL ROLERedox chemistry and participation in NAD+-dependent enzyme systems
RESEARCH QUESTIONAge-related metabolism, mitochondrial function, cellular stress, and disease-model pathways
NOT ESTABLISHED FOR DIRECT NAD+More energy, anti-aging, mental clarity, weight loss, cardiovascular protection, skin renewal, immunity, addiction recovery, or athletic performance
EVIDENCE IDENTITY
CAUTION INDEX
Nausea, vomiting, gastrointestinal distress, chills, shaking, increased heart rate, and chest pressure appear in limited human or FDA adverse-event contexts.
No complete approved contraindication or interaction label exists for direct NAD+ wellness use. Incidence and long-term risk remain uncertain.
QUALITY & STORAGE
No. It is a dinucleotide coenzyme. Grouping it with peptides is a catalog convention, not a chemistry classification.
No. They are different molecules with different absorption, metabolism, formulations, and study designs.
No. It is the catalog content statement and provides no dosing, preparation, or administration direction.
No. Identity, assay, sterility, endotoxin, particulates, fill amount, and stability are separate analytical questions.
NR, NMN, niacinamide, NADH, and NAD+ require separate evidence tracking rather than a single “NAD” claim bucket.
Identity, content, sterility, endotoxin, particulates, and stability require their own methods and lot-linked records.
It distinguishes this catalog listing. It is not a dose, protocol, route, or clinical recommendation.